The uptake of these glutamine into the cancer cells are mediated by alanine-serine-cysteine-transporter-2 (ASCT2 or SLC1A5) and it was observed that there was increased expression of these transported in LC patients [104,105]. Here, SLC1A5 is linked to cancer.